VivoSeq
Other

Irae

0

Pipeline Programs

2

Active Trials

0

Companies Involved

IrAE is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

3

clinical trials

Not yet recruiting1 · 33%
Unknown status1 · 33%
Recruiting1 · 33%

Trial Activity

IL-17 Blockade to Decrease irAEs (REPLAY)
Not yet recruiting··Phase 1·NCT07237594·4 enrolled
Thymosin Alpha-1 for irAE Secondary to ICIs
Unknown status··Phase 4·NCT06178146·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)